The clinical trial is expected to enroll up to 40 patients in two stages: an initial open-label pilot (10 patients) followed by a randomized, double-blinded, sham-controlled trial (30 patients).
Given the growing interest in non-invasive neuromodulation devices for the central nervous system, the Forum on Neuroscience and Nervous System Disorders hosted a public workshop on March 2-3, 2015 to ...
This approval represents a significant regulatory milestone, making Proliv™Rx the first and only at-home neuromodulation ...
Swedish neurotech startup Flow Neuroscience has secured FDA approval for the first brain stimulation device for home use in ...
The MarketWatch News Department was not involved in the creation of this content. AUSTIN, Texas and TOKYO, Sept. 24, 2025 /PRNewswire/ --The Digital Migraine Treatment Devices Market is witnessing ...
ImagineHealth and Vivatronix partner to bring SpineX’s neuromodulation technology to global markets, enhancing recovery for neurological condition patients. Patients have been waiting for a solution ...
Auricular vagal neuromodulation therapy is a non-invasive and non-surgical treatment that could aid cardiovascular disease ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer’s and ...
Neurolief announced today that the FDA granted approval for its Proliv Rx at-home neuromodulation therapy for treating ...
The global Vagus Nerve Stimulation Market is witnessing strong momentum due to the rising prevalence of neurological disorders, increasing demand for non-invasive therapeutic solutions, growing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback